Gene patent ruling rocks biotech community

01 May 2010

A US district court has invalidated seven patents on human genes, in part based on the Federal Circuit's ruling in In re Bilski

Eileen McDermott, New York

A US district court in late March invalidated seven patents on human genes, in part based on the Federal Circuit's ruling in In re Bilski. Judge Robert Sweet of the US District Court for the Southern District of New York ruled in a 152-page decision (Association for Molecular Pathology et al v USPTO and Myriad Genetics) that the US patents at issue are invalid.

The decision was a win for the American Civil Liberties Union (ACLU), the Public Patent Foundation (PUBPAT) and their clients, which included a number of breast cancer and women's health groups, individual women, geneticists and scientific associations.

The disputed claims of the patents are associated with the BRCA1 and BRCA2 genes and the genetic tests for ovarian and breast cancer linked to those genes. The patents are held by Myriad Genetics.

"The precedent-setting ruling marks the first time...



Only subscribers have complete access to Managing IP Magazine, log in or subscribe now.

Alternatively take a free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).

Subscribe Now

This article is available to subscribers. Please click subscribe to read the rest of the article.

Subscribe

Take a free trial

Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.

Take a free trial


INTA Daily News 2012

Read this year's INTA Daily News - published daily by Managing IP direct from the 134th INTA Annual Meeting in Washington DC

null null null
null null

May 2012

Do you want to be famous?

Famous, well-known, notorious, reputed: everyone wants enhanced protection for their trade marks. But should they, and what does it mean if it is? Emma Barraclough explains



Most read articles

Poll

Will the new post grant and inter partes review proceedings result in more litigators practising pro hac vice before the USPTO?







Supplements